IMAB | I-Mab Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.0400 - 1.0800
52 Week Range	0.9900 - 2.5360
Beta	1.03
Implied Volatility	450.31%
IV Rank	58.29%
Day's Volume	66,277
Average Volume	193,701
Shares Outstanding	77,023,302
Market Cap	81,644,700
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-01-17

Valuation
Profitability
Growth
Health
P/E Ratio	-0.47
Forward P/E Ratio	-0.74
EPS	-2.26
1YR Price Target	18.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	34
Country	China
Website	IMAB

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-acting recombinant human growth hormone,or rhGH; lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia.

IMAB's peers: BGNE, KRYS, IMVT, MRTX, FHTX, STTK, GLUE, KYMR, NRIX, LYEL, CGEM, THRX, RVMD, GRCL, DSGN, ERAS, ASND, APLS, AKRO, BPMC

*Chart delayed

Analyzing fundamentals for IMAB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see IMAB Fundamentals page.

Watching at IMAB technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on IMAB Technicals page.